已收盤 11-20 16:00:00 美东时间
-1.540
-2.37%
11月21日,TG Therapeutics Inc.(TGTX)收跌2.37%,报63.34美元,成交额1.34亿美元,市值95.74亿美元。 行情数据 •...
11-21 05:53
数据显示,PowerShares Exchange-Traded Fund前十大重仓股合计占基金资产的35.0268%。 其中,第一大重仓股为TG Thera...
11-17 07:21
11月13日,TG Therapeutics Inc.(TGTX)收跌1.82%,报64.56美元,成交额1.03亿美元,市值97.58亿美元。 行情数据 •...
11-13 05:55
今日重点评级关注:花旗:维持Faeth Therapeutics"买入"评级,目标价从55美元升至60美元;HC Wainwright & Co.:维持Ocular Therapeutix"买入"评级,目标价从25美元升至28美元
11-11 10:50
Evercore ISI Group analyst Michael DiFiore maintains TG Therapeutics (NASDAQ:TGTX) with a Outperform and lowers the price target from $73 to $71.
11-10 22:12
最新财报显示,TG Therapeutics Inc.2026财年第3季度实现: 营业收入:2.6亿美元 同比:增长60.74% 每股收益:0.39美元 同比...
11-10 17:00
<span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• # TG Therapeutics 2026年第三季度业绩回顾摘要 ## 1. 财务业绩:**营业收入(Revenue):** - 全球总营收约为2.599亿美元($259.9 million) - 美国BRIUMVI净产品收入为2.326亿美元($232.6 million / $233 million) - 总净产品收入为2.40亿美元($240 million),其中包括向ex-U.S.合作伙伴Neuraxpharm销售的740万美元产品收入 - 许可、里程碑、特许权使用费及其他收入为1,990万美元($19.9 million),其中包含来自
11-10 12:27
Biotech ETFs face a pivotal week as Summit Therapeutics (NASDAQ:SMMT) approaches a key FDA decision, while fresh drug-development updates and Hims & Hers Health Inc (NYSE:HIMS) partnership with Eli Lilly And Co (NYSE:LLY) put healthcare’s growth prospects in focus. Healthcare stocks have shown resil...
11-10 00:51
TG Therapeutics (NASDAQ:TGTX) raises FY2026 sales outlook from $950.000 million to $1.000 billion vs $960.306 million estimate.
11-09 20:03
TG Therapeutics (NASDAQ:TGTX) reported quarterly earnings of $0.35 per share which beat the analyst consensus estimate of $0.34 by 2.94 percent. This is a 85.6 percent decrease over earnings of $2.43 per share from the same period last year. The company reported quarterly sales of $259.936 million w...
11-09 20:02